Key result
Impella is linked to ~32% higher mortality vs IABP, but not in randomized trials.
Why the study?
Although Impella provides greater hemodynamic support than IABP in cardiogenic shock, comparative clinical outcomes between the devices remained uncertain.
Does Impella reduce mortality and adverse outcomes compared to intra-aortic balloon pump in adults with cardiogenic shock?
Meta-Analysis (n=36,023)
Yes
Does Impella reduce mortality and adverse outcomes compared to intra-aortic balloon pump in adults with cardiogenic shock?
In a meta-analysis of patients with cardiogenic shock, Impella was associated with higher mortality and adverse events compared to IABP, though mortality differences were not seen in randomized trials, suggesting confounding in observational data.
Answers are grounded in this paper and cite their sources.
Suggests preferring IABP over Impella in cardiogenic shock; leaves open optimal device selection pending larger RCTs.
Cardiogenic shock remains associated with mortality despite advances in revascularization and critical care. Although Impella provides greater hemodynamic support than intra-aortic balloon pump (IABP), comparative outcomes remain uncertain. We conducted a systematic review and meta-analysis comparing Impella with IABP in adults with cardiogenic shock. PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched from inception through August 2026. Randomized controlled trials and observational studies comparing Impella with IABP were included. Secondary outcomes included recurrent myocardial infarction, renal replacement therapy (RRT), major bleeding, stroke, vascular complications, and mortality with major bleeding. Random-effects models generated pooled risk ratios (RRs) with 95% confidence intervals (CIs). Prespecified subgroup analyses examined study design and Impella device type. Eleven studies comprising 36,023 participants were included. Impella was associated with higher all-cause mortality than IABP (RR 1.32, 95% CI 1.17–1.48; I 2 = 90.7%). Mortality did not differ significantly in randomized trials, with differences between study-design subgroups ( P = 0.0022). Impella was associated with increased RRT (RR 2.56, 95%CI 1.27–5.18), major bleeding (RR 1.64, 95% CI 1.42–1.90), stroke (RR 1.47, 95%CI 1.25–1.74), and vascular complications (RR 3.30, 95% CI 2.68–4.06). Mortality with major bleeding was also higher with Impella (RR 1.34, 95%CI 1.17–1.54). Recurrent myocardial infarction did not differ significantly (RR 0.76, 95%CI 0.40–1.46). Impella was associated with higher mortality and adverse outcomes compared with IABP. However, the mortality association was not observed in randomized evidence, highlighting potential confounding in observational studies. Further randomized comparisons of contemporary Impella CP and IABP are warranted. PROSPERO ID: (CRD420261428842).
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a meta-analysis in Cardiogenic shock (n=36,023). Impella vs. Intra-aortic balloon pump (IABP) was evaluated on All-cause mortality (RR 1.32, 95% CI 1.17-1.48, p=<0.0001). Impella was associated with a higher risk of all-cause mortality compared with intra-aortic balloon pump support, although this association was not observed in randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: